Showing results (401-410 of 416) with videos related to
Sort By:
Pageof 42
Open Forum Infectious Diseases|July 7, 2022
Clinical Characteristics, Health Care Utilization, and Outcomes Among Patients in a Pilot Surveillance System for Invasive Mold Disease-Georgia, United States, 2017-2019Jeremy A W Gold, Andrew Revis, Stepy Thomas, et al.Journal of Investigational Allergology & Clinical Immunology|May 23, 2015
Consensus document on allergic conjunctivitis (DECA)M C Sánchez-Hernández, J Montero, C Rondon, et al.Cell Death & Disease|May 20, 2024
CDK9 inhibition as an effective therapy for small cell lung cancerL Valdez Capuccino, T Kleitke, B Szokol, et al.Molecular Therapy. Nucleic Acids|March 14, 2022
Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic toolVicente Herrero-Aguayo, Prudencio Sáez-Martínez, Juan M Jiménez-Vacas, et al.Ebiomedicine|March 12, 2023
Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidenceAntonio C Fuentes-Fayos, Miguel E G-García, Jesús M Pérez-Gómez, et al.Biology|December 30, 2025
Comparative Genomic and Microenvironmental Profiles of Hereditary and Sporadic TNBC in Colombian WomenYina T Zambrano-Ordoñez, Alejandro Mejía-Garcia, Julieta M Ramírez-Mejía, et al.Leukemia|July 24, 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG miceJ Etchin, J Montero, A Berezovskaya, et al.Ebiomedicine|January 7, 2020
Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancerJuan M Jiménez-Vacas, Vicente Herrero-Aguayo, Antonio J Montero-Hidalgo, et al.Science Advances|October 2, 2024
SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancerAntonio J Montero-Hidalgo, Juan M Jiménez-Vacas, Enrique Gómez-Gómez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialFrancois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.Pageof 42